Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Ziller V Schüssel K Czeche S Franzmann A Klöckner D Quinzler R Schulz M Möhrke W Hadji P

36^th European Symposium on Calcified Tissues, 23. - 27.05.2009, Vienna, Austria.

ECTS 2009, Wien; Poster: Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Bone 2009; 44 (Suppl. 2): S449 (Abstract P511)

Conflicts of interests: W.Moehrke, Procter and Gamble Pharmaceuticals, Employee; M.Schulz, Procter and Gamble Pharmaceuticals, Grant; P.Hadji, Procter and Gamble Pharmaceuticals, Consultant.

Pharmakoepidemiologische Auswertungen des DAPI

Impact On Antihypertensive Prescribing After The Dear Healthcare Professional Letter On Increased Risk Of Skin Cancer Related To Hydrochlorothiazide

Infliximab And Etanercept Biosimilars And Originators: Learnings From Regional Market Dynamics In Germany

Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave

Verordnungsqualität oraler Fluorchinolone in den deutschen Bundesländern 2014 bis 2019

Use of fixed‑dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia

Masterthesis - Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave